Companies in the Barrow All-Cap Core Fund are merger targets four times more than the market at large and that's because the fund's managers take a private equity approach to stock-picking, says David Bechtel, principal at Barrow Funds. Bechtel says the fund has 20% of its assets in health care stocks presently with Questcor being its weightiest position. The value-based fund also looks for a heavy margin of safety when selecting stocks, which has led it to invest in Smith & Wesson and Raytheon.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.